丹麦、英格兰、挪威和瑞典结直肠癌的手术治疗与生存:一项基于人群的研究
该基于人群研究利用四国国家结直肠癌登记数据,分析2010至2012年确诊的139457例成人结直肠腺癌患者,比较手术切除比例与生存差异。结果显示英格兰结肠癌和直肠癌生存低于挪威和瑞典,丹麦结肠癌生存亦较低;生存与手术切除比例平行,老年和晚期患者手术选择差异可能部分解释国际生存差异。
要点
- 英格兰结肠癌3年生存63.9%低于挪威69.5%和瑞典72.1%,丹麦65.7%亦低于挪威和瑞典。
- 英格兰直肠癌3年生存69.7%低于丹麦72.5%、瑞典74.1%和挪威75.0%。
- 结肠癌手术切除比例英格兰68.4%低于瑞典81.3%;直肠癌英格兰59.9%低于瑞典70.8%。
核心结论
- 英格兰结肠癌和直肠癌生存以及丹麦结肠癌生存低于挪威和瑞典,生存与手术切除的相对提供程度平行。
- 手术选择差异,尤其是75岁以上或晚期患者,可能部分解释国际结直肠癌生存差异。
研究设计与样本
- 基于人群研究,收集丹麦、英格兰、挪威和瑞典国家结直肠癌登记中2010年1月1日至2012年12月31日确诊的18-99岁原发性浸润性结直肠腺癌患者数据。
- 共纳入139457例成人患者:丹麦12958例,英格兰97466例,挪威11450例,瑞典17583例。
- 采用多变量模型估计年龄标准化净生存,按分期和年龄比较手术切除比例,并用逻辑回归预测若按最佳表现国家治疗时患者的手术状态。
主要发现
- 结肠癌3年生存英格兰63.9%(95% CI 63.5-64.3)和丹麦65.7%(64.7-66.8)低于挪威69.5%(68.4-70.5)和瑞典72.1%(71.2-73.0)。
- 直肠癌3年生存英格兰69.7%(69.1-70.3)低于丹麦72.5%(71.1-74.0)、瑞典74.1%(72.7-75.4)和挪威75.0%(73.1-76.8)。
- II期直肠癌3年生存英格兰86.4%(85.0-87.6)低于挪威94.1%(91.5-96.0)和瑞典92.9%(90.8-94.6),亦低于丹麦91.2%(88.8-93.1)。
- III期直肠癌3年生存英格兰75.5%(74.2-76.7)低于挪威83.4%(80.1-86.1)和瑞典80.6%(78.2-82.7)。
- IV期结肠癌3年生存英格兰20.5%(19.9-21.1)低于挪威33.0%(31.0-35.1)和瑞典23.7%(22.0-25.3),亦低于丹麦23.5%(21.9-25.1)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Survival from colorectal cancer has been shown to be lower in Denmark and England than in comparable high-income countries. We used data from national colorectal cancer registries to assess whether differences in the proportion of patients receiving resectional surgery could contribute to international differences in colorectal cancer survival. METHODS: In this population-based study, we collected data from all patients aged 18-99 years diagnosed with primary, invasive, colorectal adenocarcinoma from Jan 1, 2010, to Dec 31, 2012, in Denmark, England, Norway, and Sweden, from national colorectal cancer registries. We estimated age-standardised net survival using multivariable modelling, and we compared the proportion of patients receiving resectional surgery by stage and age. We used logistic regression to predict the resectional surgery status patients would have had if they had been treated as in the best performing country, given their individual characteristics. FINDINGS: We extracted registry data for 139 457 adult patients with invasive colorectal adenocarcinoma: 12 958 patients in Denmark, 97 466 in England, 11 450 in Norway, and 17 583 in Sweden. 3-year colon cancer survival was lower in England (63·9%, 95% CI 63·5-64·3) and Denmark (65·7%, 64·7-66·8) than in Norway (69·5%, 68·4-70·5) and Sweden (72·1%, 71·2-73·0). Rectal cancer survival was lower in England (69·7%, 69·1-70·3) than in the other three countries (Denmark 72·5%, 71·1-74·0; Sweden 74·1%, 72·7-75·4; and Norway 75·0%, 73·1-76·8). We found no significant differences in survival for patients with stage I disease in any of the four countries. 3-year survival after stage II or III rectal cancer and stage IV colon cancer was consistently lower in England (stage II rectal cancer 86·4%, 95% CI 85·0-87·6; stage III rectal cancer 75·5%, 74·2-76·7; and stage IV colon cancer 20·5%, 19·9-21·1) than in Norway (94·1%, 91·5-96·0; 83·4%, 80·1-86·1; and 33·0%, 31·0-35·1) and Sweden (92·9%, 90·8-94·6; 80·6%, 78·2-82·7; and 23·7%, 22·0-25·3). 3-year survival after stage II rectal cancer and stage IV colon cancer was also lower in England than in Denmark (stage II rectal cancer 91·2%, 88·8-93·1; and stage IV colon cancer 23·5%, 21·9-25·1). The total proportion of patients treated with resectional surgery ranged from 47 803 (68·4%) of 69 867 patients in England to 9582 (81·3%) of 11 786 in Sweden for colon cancer, and from 16 544 (59·9%) of 27 599 in England to 4106 (70·8%) of 5797 in Sweden for rectal cancer. This range was widest for patients older than 75 years (colon cancer 19 078 [59·7%] of 31 946 patients in England to 4429 [80·9%] of 5474 in Sweden; rectal cancer 4663 [45·7%] of 10 195 in England to 1342 [61·9%] of 2169 in Sweden), and the proportion of patients treated with resectional surgery was consistently lowest in England. The age gradient of the decline in the proportion of patients treated with resectional surgery was steeper in England than in the other three countries in all stage categories. In the hypothetical scenario where all patients were treated as in Sweden, given their age, sex, and disease stage, the largest increase in resectional surgery would be for patients with stage III rectal cancer in England (increasing from 70·3% to 88·2%). INTERPRETATION: Survival from colon cancer and rectal cancer in England and colon cancer in Denmark was lower than in Norway and Sweden. Survival paralleled the relative provision of resectional surgery in these countries. Differences in patient selection for surgery, especially in patients older than 75 years or individuals with advanced disease, might partly explain these differences in international colorectal cancer survival. FUNDING: Early Diagnosis Policy Research Grant from Cancer Research UK (C7923/A18348).
引用
- Benitez Majano S, Di Girolamo C, Rachet B, et al. Surgical treatment and survival from colorectal cancer in Denmark, England, Norway, and Sweden: a population-based study. Lancet Oncol. 2018. PMID: 30545752. doi:10.1016/S1470-2045(18)30646-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。